Physician profile
Patrick Gillespie
NPI 1902850084
$784.66
in general payments reported to CMS, 2019-2025
18 companies · $59.22 in 2025
The $59.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $140 · 2021: $141 · 2022: $133 · 2023: $31.56 · 2024: $42.21 · 2025: $59.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $132.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $153.49 | 2019 | |
| Merck Sharp & Dohme LLC | $101.02 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $78.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $72.83 | 2020-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.37 | 2020-2024 | Xifaxan, Trulance |
| Pfizer INC. | $54.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.27 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $30.51 | 2025 | Voquezna |
| Amgen INC. | $26.02 | 2021-2022 | |
| Abbvie INC. | $25.87 | 2021 | |
| Kci USA, INC. | $20.80 | 2022 | |
| Acadia Pharmaceuticals INC | $20.35 | 2020 | |
| Aimmune Therapeutics, INC. | $17.90 | 2022 | |
| Next Science LLC | $15.48 | 2021 | |
| Axsome Therapeutics, INC. | $14.45 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.26 | 2025 | Caplyta |
| Lilly USA, LLC | $13.37 | 2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $13.21 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.